Bevacizumab
Treatment for Macular Degeneration
Typical Dosage: 1.25 mg intravitreal injection every 4-8 weeks
Effectiveness
88%
Safety Score
45%
Clinical Trials
130
Participants
55K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
1.25 mg intravitreal injection every 4-8 weeks
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$800
Monitoring:$750
Side Effect Mgmt:$300
Total Annual:$1,850
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$10,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$2,010.87
Active Clinical Trials
1 active trial recruiting for Bevacizumab in Macular Degeneration
Aflibercept and Bevacizumab for Diabetic Maculopathies
NCT06850571RECRUITINGPHASE4
102 participants
INTERVENTIONAL
Baghdad, Iraq
Started: Feb 20, 2025
Completed Clinical Trials
14 completed trials for Bevacizumab in Macular Degeneration
Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
NCT04138420COMPLETED
38 participants
OBSERVATIONAL
Naples, Italy
Started: Jan 25, 2017
Systemic Avastin Therapy in Age-Related Macular Degeneration
NCT00531024COMPLETEDPHASE2, PHASE3
30 participants
INTERVENTIONAL
Vienna, Austria
Started: Aug 1, 2005
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
NCT01327222COMPLETEDPHASE3
20 participants
INTERVENTIONAL
Milan, Italy
Started: Feb 1, 2011
VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
NCT00727753COMPLETED
54 participants
OBSERVATIONAL
Zurich, Switzerland
Started: Jul 1, 2008
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)
NCT06190093COMPLETEDPHASE3
400 participants
INTERVENTIONAL
Arcadia, United States +60 more
Started: Jan 24, 2024
Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
NCT00359164COMPLETEDPHASE2
36 participants
INTERVENTIONAL
Vancouver, Canada
Started: Jul 1, 2006
Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
NCT03744806COMPLETED
48 participants
OBSERVATIONAL
Started: Jan 1, 2015
Combination Therapy for Age-Related Macular Degeneration.
NCT00376701COMPLETEDPHASE2
103 participants
INTERVENTIONAL
Edmonton, Canada +4 more
Started: Sep 1, 2006
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03844074COMPLETEDPHASE3
61 participants
INTERVENTIONAL
Hurstville, Australia +8 more
Started: Oct 1, 2018
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03834753COMPLETEDPHASE3
228 participants
INTERVENTIONAL
Tucson, United States +49 more
Started: Jun 25, 2019
Single or Combined Protocols for NV-AMD
NCT03552770COMPLETEDPHASE4
109 participants
INTERVENTIONAL
Started: Nov 23, 2014
Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration
NCT01032109COMPLETEDNA
45 participants
INTERVENTIONAL
Kumamoto, Japan
Started: Oct 1, 2006
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00556348COMPLETEDPHASE4
500 participants
INTERVENTIONAL
Started: Nov 1, 2005
Bevacizumab for Neovascular Age-related Macular Degeneration
NCT01306591COMPLETEDNA
210 participants
INTERVENTIONAL
Beijing, China
Started: Jan 1, 2008
Showing 20 of 130 total trials